Federated Hermes Inc. Raises Stock Holdings in DaVita Inc. (NYSE:DVA)

Federated Hermes Inc. increased its stake in DaVita Inc. (NYSE:DVA) by 11.3% during the 4th quarter, Holdings Channel reports. The firm owned 147,329 shares of the company’s stock after purchasing an additional 14,948 shares during the quarter. Federated Hermes Inc.’s holdings in DaVita were worth $22,033,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of DVA. Aviva PLC increased its holdings in shares of DaVita by 427.7% in the 4th quarter. Aviva PLC now owns 27,921 shares of the company’s stock worth $4,176,000 after buying an additional 22,630 shares during the last quarter. Resona Asset Management Co. Ltd. purchased a new position in DaVita in the fourth quarter worth $2,149,000. World Investment Advisors bought a new position in DaVita in the fourth quarter valued at $222,000. Huntington National Bank raised its position in DaVita by 17.6% during the fourth quarter. Huntington National Bank now owns 903 shares of the company’s stock valued at $135,000 after purchasing an additional 135 shares in the last quarter. Finally, Kesler Norman & Wride LLC lifted its stake in DaVita by 40.2% during the fourth quarter. Kesler Norman & Wride LLC now owns 4,874 shares of the company’s stock worth $729,000 after purchasing an additional 1,397 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on DVA. Barclays increased their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. StockNews.com cut shares of DaVita from a “buy” rating to a “hold” rating in a research report on Wednesday, April 2nd. Cowen restated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $166.33.

DaVita Price Performance

Shares of DaVita stock opened at $143.63 on Wednesday. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60. The business’s 50 day simple moving average is $153.98 and its two-hundred day simple moving average is $156.84. The stock has a market capitalization of $11.49 billion, a P/E ratio of 13.37, a price-to-earnings-growth ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Analysts forecast that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.